These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20406091)

  • 21. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells.
    Catalano A; Lazzarini R; Di Nuzzo S; Orciari S; Procopio A
    Cancer Res; 2009 Feb; 69(4):1485-93. PubMed ID: 19176370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
    Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
    J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
    Hanauske AR
    Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions.
    Falleni M; Pellegrini C; Marchetti A; Roncalli M; Nosotti M; Palleschi A; Santambrogio L; Coggi G; Bosari S
    Lung Cancer; 2005 May; 48(2):211-6. PubMed ID: 15829320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular prognostic markers in malignant mesothelioma.
    Kumar P; Kratzke RA
    Lung Cancer; 2005 Jul; 49 Suppl 1():S53-60. PubMed ID: 15950802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M; Gatzemeier U
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K; Garey JS
    Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
    Tomek S; Manegold C
    Lung Cancer; 2004 Aug; 45 Suppl 1():S103-19. PubMed ID: 15261443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
    Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
    Cesario A; Catassi A; Festi L; Imperatori A; Pericelli A; Galetta D; Margaritora S; Porziella V; Cardaci V; Granone P; Dominioni L; Russo P
    Clin Cancer Res; 2005 Mar; 11(5):2026-37. PubMed ID: 15756029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
    Strizzi L; Catalano A; Vianale G; Orecchia S; Casalini A; Tassi G; Puntoni R; Mutti L; Procopio A
    J Pathol; 2001 Apr; 193(4):468-75. PubMed ID: 11276005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
    Fennell DA; Rudd RM
    Lancet Oncol; 2004 Jun; 5(6):354-62. PubMed ID: 15172356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current options for systemic therapy in mesothelioma.
    Jackman DM
    Semin Thorac Cardiovasc Surg; 2009; 21(2):154-8. PubMed ID: 19822287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodality therapy in mesothelioma: role of chemotherapy.
    Vogelzang NJ
    Thorac Surg Clin; 2004 Nov; 14(4):531-42. PubMed ID: 15559060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Update of pemetrexed in thoracic oncology].
    Brechot JM; Morère JF
    Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.
    Opitz I; Lardinois D; Arni S; Hillinger S; Vogt P; Odermatt B; Rousson V; Weder W
    Eur J Cardiothorac Surg; 2007 May; 31(5):773-8. PubMed ID: 17350855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
    Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
    J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.